Detalhe da pesquisa
1.
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
J Allergy Clin Immunol;
153(2): 479-486.e4, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37866460
2.
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
J Allergy Clin Immunol;
150(6): 1498-1506.e2, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36096203
3.
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
N Engl J Med;
378(20): 1908-1919, 2018 05 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29768139
4.
Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis.
BMC Med Res Methodol;
21(1): 250, 2021 11 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34773974
5.
Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
Clin Exp Rheumatol;
36(4): 668-675, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29533755
6.
Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.
Clin Exp Rheumatol;
35 Suppl 108(6): 19-26, 2017.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27974104
7.
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
N Engl J Med;
367(25): 2396-406, 2012 Dec 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23252526
8.
Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results).
Clin Exp Rheumatol;
31(2): 302-9, 2013.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23380020
9.
Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
J Hypertens;
26(8): 1695-702, 2008 Aug.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18622250
10.
Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
Neurourol Urodyn;
27(6): 540-7, 2008.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18663723
11.
Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab.
Arthritis Rheumatol;
68(1): 218-28, 2016 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26314396
12.
Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
Arthritis Res Ther;
13(6): R202, 2011.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22152723
13.
Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study.
Curr Med Res Opin;
23(11): 2697-704, 2007 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17892634
14.
Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study.
Int Urogynecol J Pelvic Floor Dysfunct;
17(3): 239-47, 2006 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-15999217
15.
Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study.
BJU Int;
98(5): 1025-32, 2006 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16879437